The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a ...

LUBBOCK, Texas (KCBD) - The nasal spray Spravato, also known as esketamine, now acts as a first-of-its-kind treatment for those who have seen minimal or no improvement from at least two ...

Think about mental health and the impact of our Invega portfolio, Spravato, and the potential ... providing strategic near- and long-term growth catalysts for Johnson & Johnson.

Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ETCompany ParticipantsJessica Moore - Vice President, ...

Presentation Operator Good morning and welcome to Johnson and Johnson's fourth quarter 2024 earnings conference call. All ...

John­son & John­son’s bur­geon­ing de­pres­sion treat­ment Spra­va­to eclipsed $1 bil­lion in rev­enue in 2024 as the phar­ma’s neu­ro­science pipeline comes in­to view.

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

From breaking news to special features, we're on it! Join the NonStop Local Chord group and always be in the know. WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug ...

nasal spray bottle WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive ...